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ABSTRACT 
 Animal model studies and clinical trials have looked at the potential benefits of the anti-
inflammatory properties of statins in asthma management with contradictory results.  Therefore, 
the objective of this study is to determine if asthma patients on concurrent statin therapy are less 
likely to have asthma-related hospitalizations and emergency room (ER) visits.   
We conducted a retrospective cohort study using Medicaid data for 2002-2004. Asthma 
patients 18 years old were identified using the ICD9 code 493.xx, from Jul 1, 2002 through Dec 
31, 2003.  The index date for an exposed subject was any date within the identification period, 
180 days prior to which the subject had at least 1 inhaled corticosteroid (ICS) prescription and at 
least an 80% adherence rate to statins.  Medicaid beneficiaries identified as asthmatics and on 
ICS therapy, but not on statins were selected as the unexposed population.  Each subject in the 
exposed group was matched to 2 subjects from the unexposed population using propensity scores 
computed using age, gender, race, urban/rural region and Charlson Comorbidity Index.  The two 
groups were followed for 1 year beginning on the index date, and their outcomes in terms of 
hospitalizations and ER visits were compared using conditional logistic regression, further 
adjusted for adherence to ICS therapy, average number of short-acting β agonists per subject, 
prior hospitalizations, ER, lab and office visits due to asthma. 
After matching, there were 479 exposed subjects with 958 corresponding controls.  After 
adjusting for the above mentioned covariates, asthma patients not on concurrent statin therapy 
are almost two times as likely to have hospitalization and/or ER visits or both due to asthma 
(adjusted OR = 0.55; 95% CI [0.37, 0.84]; p = 0.0059), in comparison to patients on statin 
 iii 
 
therapy.  Similarly, they are also twice as likely to visit the ER due to asthma exacerbations as 
patients on statins (adjusted OR = 0.48; 95% CI [0.28, 0.82]; p = 0.0069). 
The findings of this study suggest that there may be beneficial effects of statins in 
preventing asthma exacerbations.  Further prospective investigations are required to provide 
conclusive evidence. 
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I. INTRODUCTION 
Asthma is a chronic inflammation of the airways, leading to poor air exchange that 
causes shortness of breath and wheezing.  Around 300 million across the globe1 and 22 million 
in the United States2 are afflicted with the disease leading to an annual burden of approximately 
$20.7 billion dollars (2010)3 to the U.S. health care system.  Medications used in the 
management of the disease are categorized into acute relief and long-term maintenance, with 
Inhaled Corticosteroids (ICSs) being the most widely prescribed for long-term control of the 
condition.  Recently, there has been considerable discussion about the anti-inflammatory 
properties of statins and hence their potential therapeutic benefit in the treatment of asthma.   
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzymes A (HMG CoA) 
reductase, conventionally prescribed as anti-hyperlipidemics.  However, their beneficial anti-
inflammatory properties have led to several studies evaluating their role in the management of 
asthma.  Animal model studies4-10 suggest various mechanisms of action by which statins may 
have potential benefits in the treatment of asthma with promising results.  There have been two 
published clinical trials11,12 that have reached conclusions that conflict the findings of the animal 
model studies.  Here, the authors failed to find statins effective for the short-term therapy of 
asthmatic inflammation, but one of them documented a reduction in the sputum macrophage 
counts in mild to moderate atopic asthma.  It should be noted that the clinical trials have sample 
size limitations. 
 2 
 
There has been one retrospective analysis13 so far that investigates the relationship 
between statins and asthma outcomes using the Medco National Integrated Database.  This study 
concludes that statin exposure is independently associated with a significant 33% relative risk 
reduction for recurrent asthma- related hospitalizations and emergency room (ER) visits. 
Some researchers are of the opinion that we already have effective medications for the 
treatment of allergic asthma in the form of ICS and that adding a statin to an appropriate dose of 
ICS would not provide any additional benefit for patients with asthma.14  But, in spite of ICS 
being an effective therapy, the burden of asthma, in terms of healthcare dollars and loss of 
productivity, continues to increase.3,15  
Thus, we are left with exciting data but a nagging dilemma and results so far clearly 
suggest that more studies investigating the potential role of statins in the management of asthma 
are required to make any clinical or policy-guiding decisions.  In light of the evidence so far, the 
purpose of this study is to investigate the potential role of statins on asthma outcomes in 
particular, using a retrospective cohort study design, with the specific objectives being: 
1. To describe the baseline characteristics such as age, gender, race of Medicaid 
beneficiaries with asthma who are on statin therapy and those not on statin therapy. 
2. To compare the outcomes, using ER visits and hospitalizations as a measure, amongst 
asthmatic Medicaid beneficiaries on statin therapy to those not on statin therapy. 
3. To compare the costs incurred by asthmatic Medicaid beneficiaries on statin therapy to 
those not on statin therapy including the prescription costs, ER visits and hospitalization 
costs.  
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II. LITERATURE REVIEW 
Asthma Prevalence and Costs 
Approximately 300 million people across the globe suffer from asthma according to the 
executive summary of the Global Initiative for Asthma (GINA) Dissemination Committee 
Report. 1  The GINA program was initiated in 1989 in an effort to raise awareness about the 
increasing prevalence of asthma worldwide, with the Dissemination Committee being 
responsible for providing data on the burden of asthma.  Estimates from the report also suggest 
that asthma prevalence increases globally by 50% every decade with some of the highest 
numbers seen amongst data from developed countries such as United Kingdom  (>15%), New 
Zealand (15.1%), Australia (14.7%), the Republic of Ireland (14.6%), and the United States 
(10.9%).   Numbers from the World Health Organization (WHO) fact sheet on bronchial asthma 
attribute 180,000 deaths globally to asthma each year and estimate that the economic costs 
associated with asthma exceed those of tuberculosis and HIV/AIDS combined.16  The financial 
burden on patients with asthma in different western countries ranges from $300 to $1,300 per 
patient per year17 with those suffering from severe asthma being responsible for 50% of all direct 
and indirect costs even though this patient population represents just 10-20% of all those 
suffering from the condition.15,18  Thus, the economic burden disproportionately affects those 
with the most severe disease. 
In accordance with the 2007 National Asthma Education and Prevention Program Expert 
Panel Report 32 more than 22 million have asthma in the U.S.  The burden of asthma affects 
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patients and their families in terms of lost work and school days, lessened quality of life, and 
avoidable emergency department visits, hospitalizations and deaths.   Estimates of the annual 
costs of asthma in the U.S. range between $12.7 and $20.7 billion.3,19   Researchers at the 
University of Georgia developed an estimate of the lifetime costs of asthma for children born in 
the year 2000, documenting the total lifetime impact of asthma for this birth cohort to be $7.2 
billion.20  They also concluded that losses in productivity are significant and thus interventions 
that help better manage the disease, reduce the number of missed work days, and decrease the 
number of asthma exacerbations could have significant indirect cost savings.  
The National Surveillance for Asthma 2001- 2003 summary21 reported 55.6% of current 
asthmatics as having one or more attacks during the preceding 12 months.  Amongst other 
statistics, the summary mentions an average annual 61.2 office visits, 6.7 hospital outpatient 
visits and 8.8 emergency department visits for asthma per 100 persons with current asthma.  
Analysis of cross-sectional survey data from an on-going community-based panel study of adults 
with asthma based in northern California reported $4,912 as the total per person annual costs of 
asthma with hospital admissions and indirect costs due to loss in productivity accounting for 
9.75% and 35% of the total costs respectively.22  A review of various cost of illness studies 
estimated the mean direct cost of asthma per year per patient to be $1,100 approximately, stating 
it accounted for 50% of total costs.23  Thus, it is evident that significant healthcare savings can be 
accrued if costs due to hospitalizations and loss of productivity are prevented via better 
management of the condition, preventing asthma exacerbations.  
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Asthma Treatment 
Asthma has been defined as “a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role; in particular mast cells, eosinophils, neutrophils 
(especially in sudden onset, fatal exacerbations, occupational asthma, and patients who smoke), 
T lymphocytes, macrophages and epithelial cells. In susceptible individuals this inflammation 
causes recurrent episodes of coughing (particularly at night or early in the morning), wheezing, 
breathlessness, and chest tightness.  These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or with treatment.”2  
Airway inflammation is said to bring about a majority of the changes in the airway and thus 
future studies are targeted at determining if different treatment approaches will benefit the 
different patterns of inflammation.  Definitive causes that bring about the inflammatory process 
have not yet been established although genetics, environmental factors as well as the balance 
between Th1- and Th2-type cytokine responses are amongst a few that have been suggested.24   
Medications that attenuate the inflammation are the most effective in the management of 
asthma symptoms and are currently classified as quick relief or long-term control medications.25  
Controller medications are generally prescribed when quick-acting bronchodilators are needed to 
relieve symptoms more than two days a week or more than twice a month for night time 
awakenings caused by exacerbations.2,24  Figure I is a schematic diagram illustrating the stepwise 
control of the disease. 
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Inhaled Corticosteroids (ICSs) are the most consistently effective long-term control 
medications at all steps of care for persistent asthma.  They reduce airway hyper responsiveness, 
inhibit inflammatory cell migration and activation and block late phase reaction to allergens.2  
ICSs reduce impairment and risk of exacerbations but evidence to suggest they prevent the 
progressive decline in lung function is lacking.26,27  Strategies that achieve asthma control 
without using high doses of ICS are desirable as the dose therapeutic response curve for these 
medications is relatively flat whereas the dose-systemic absorption curve appears to be linear.28  
STEP 1 
 
Preferred: 
SABA  
STEP 2 
 
Preferred: 
Low-dose 
ICS 
 
Alternative: 
Cromolyn, 
LTRA, 
Nedocromil, 
Theophylline 
STEP 3 
 
Preferred: 
Low-dose 
ICS + LABA 
or medium 
dose ICS 
 
Alternative: 
Low dose 
ICS + LTRA, 
Zileuton, 
Theophylline 
STEP 4 
 
Preferred: 
Medium dose 
ICS + LABA 
 
Alternative: 
Medium dose 
ICS + LTRA, 
Zileuton, 
Theophylline 
STEP 5 
 
Preferred: 
High dose 
ICS + LABA 
 
AND 
 
Consider 
Omalizumab 
for patients 
who have 
allergies 
STEP 6 
 
Preferred: 
High dose 
ICS + LABA 
+ oral 
corticosteroid 
 
AND 
 
Consider 
Omalizumab 
for patients 
who have 
allergies 
 
 
Intermittent 
Asthma 
Persistent Asthma: Daily Medication 
Figure I. Stepwise approach for Asthma Management in Adults (National Asthma Education and 
Prevention Program Expert Panel Report 3)2 
• SABA – Short Acting β Agonists  
• LABA – Long Acting β Agonists 
• LTRA – Leukotriene Receptor Antagonists 
 
 
 7 
 
This indicates an increasing availability of the drug in the systemic circulation with increasing 
doses; however, the therapeutic benefits achieved do not necessarily differ with higher doses.  
Cromolyn sodium and nedocromil, immunomodulators that prevent binding of IgE to the 
receptors on basophils and mast cells, leukotriene modifiers, long-acting β agonists (LABAs) and 
methylxanthines are some of the other long-term control medications.  Leukotriene modifiers 
and LABAs are generally used in combination with ICSs.  Anticholinergics, short-acting β 
agonists (SABAs) and systemic corticosteroids are the quick-relief medications used to treat 
acute symptoms and exacerbations.2,24  
 
Statins in the Treatment of Asthma 
Recently statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzymes A (HMG-CoA), 
have been shown to have promising therapeutic potential in mediating inflammatory processes.29-
32  They are amongst the most widely prescribed medicines and are primarily used to treat 
hyperlipidemia and prevent cardiovascular diseases.  However, in the past decade studies have 
shown statins to be effective in animal model studies as well as clinical trials of rheumatoid 
arthritis33-35, autoimmune encephalomyelitis36,37, inflammatory colitis38,39 and even psoriasis40 
due to their anti-inflammatory properties.  Given this, there has been some discussion pertaining 
to the use of statins in the treatment of asthma and various studies have suggested asthma 
management as an emerging indication for statins.41-45  
Certain researchers believe that the addition of a statin to ICS therapy in clinical practice 
will not prove beneficial in the management of asthma referring to this setting as a ‘snake oil 
panacea’14, while others believe it might actually be harmful.46  These have just been voiced as 
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opinions in the literature and there is lack of evidence in support of these concerns.  
Alternatively, the majority of the arguments are in favor of adding a statin to ICS therapy, and 
not without evidence.  A number of studies have shown the beneficial effects of statins in the 
management of asthma and these will be discussed shortly.  It has been suggested that statin 
treatment could improve asthma control in smokers with asthma who are insensitive to treatment 
with ICS.47,48  Additionally, some patients with severe asthma require additional oral 
corticosteroids, a long-term treatment which is associated with such side effects as adrenal 
suppression, growth suppression, and osteoporosis.42,49  Statins on the other hand are one of the 
most widely prescribed medications and have a better safety profile.  In certain cases severe 
asthma is steroid-resistant, and hence alternative therapy is needed for such patients.49  
It has been suggested that the pleiotropic effects of statins are independent of their lipid-
lowering abilities45, 50 and are in part related to their lipophilicity, and thus each compound in the 
class exhibits different effects on the inflammatory cells.  Simvastatin and atorvastatin are said to 
have the greatest anti-inflammatory potential.51  The rationale behind this observation is the 
preferential ability of lipophilic statins to enter a variety of somatic cells, in contrast with 
hydrophilic compounds such as pravastatin that are reliant on active uptake by hepatocytes to 
mediate their metabolic activity.52  Hence, important within class differences exist between the 
drugs. 
A few animal model studies suggest that statins might have potential as therapeutic 
agents in the treatment of asthma.4-10  Y. Chiba et al. have carried out a number of such studies 
with lovastatin.  Their experiments with rats suggest that systemic lovastatin inhibits antigen-
induced bronchial smooth muscle hyper-responsiveness in addition to reducing the increased cell 
number in bronchoalveolar lavage (BAL) fluids and histological changes induced by antigen 
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exposure.4  They also demonstrated that levels of Immunoglobulin E in sera and interleukins -4, -
6, and -13 in the bronchoalveolar lavage fluids were not significantly changed.  The authors have 
carried out similar experiments in mice, with findings that support the beneficial role of statins in 
asthma management.5  The proposed mechanism of action for this observation is that statins 
inhibit the geranylgeranylation of a monomeric GTP binding protein RhoA and its downstream 
metabolites, which are involved in the agonist induced Ca2+ sensitization of airway smooth 
muscle contraction.  The RhoA/ RhoA kinase pathway is now being investigated as the new 
target for the treatment of airway hyper responsiveness. 
Another animal model study conducted by Y. Chiba et al. shows that lovastatin 
ameliorates the antigen induced infiltration of inflammatory cells such as eosinophils into the 
airways.6  Inhibition of the geranylgeranylation of Rho family GTPases in leukocytes has been 
cited as the proposed mechanism again.  Similarly, a study conducted by McKay and colleagues 
showed the inhibitory effects of simvastatin on inflammatory cell infiltration in a murine model 
of allergic asthma.7  They also showed a reduction in the BAL cytokine levels which is 
contradictory to the results of the experiments conducted by Y. Chiba and colleagues.  
Similarly, experiments have been conducted with pravastatin and simvastatin showing 
beneficial effects whereby the former was shown to suppress systemic sensitization to allergen 
due to inhibition of interleukin 178 and the latter prevents the infiltration of inflammatory cells in 
the bronchoalveolar lavage fluids9 and has been shown to reduce the CD4 T cell numbers.10 
Apart from the animal model studies described above, two clinical trials have been 
conducted, whereby the relationship between statins and asthma has been further explored.  A 
randomized double-blind crossover placebo controlled trial was designed to investigate the effect 
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of oral atorvastatin on measures of asthma control and airway inflammation in 54 adults with 
allergic asthma receiving inhaled corticosteroids alone.11  The authors found no clinically 
important improvements in a range of clinical indices of asthma control despite expected 
changes in serum lipids and thus concluded that statins were ineffective for the short-term 
therapy of asthmatic inflammation.  However, a change in the airway inflammation, as well as a 
reduction in the sputum macrophage count was observed indicating that statins could have 
beneficial effects in other chronic lung diseases. 
A similar clinical trial using oral simvastatin was conducted using 16 patients with 
asthma whereby the authors found no improvement in asthma symptoms, pulmonary function or 
measures of asthmatic inflammation.12  All anti-inflammatory asthma medications including 
inhaled corticosteroids were tapered and stopped completely for the duration of this study, which 
was the major difference in the protocols of the two clinical trials.  However, a small sample size 
is one of the major limitations of the above cited clinical trials and thus the results should be 
interpreted cautiously.   
In 2007, E. Stanek and colleagues conducted an observational study using the Medco 
National Integrated Database to explore the relationship between statin treatment and asthma.  
This is the first observational study to investigate the topic.13  A total of 6,574 inhaled 
corticosteroid-treated adult asthmatics were studied and statin exposure was independently 
associated with a significant 33% relative risk reduction for recurrent asthma-related 
hospitalization/ER visits over 12 months.  They included subjects who had received an ICS 
prescription anytime from January 2006 to December 2006 and had recorded at least one asthma 
specific hospitalization/emergency room visit in the 12 months prior to the index ICS 
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prescription selected.  These were then stratified by statin exposure following evidence of an 
index ICS prescription. 
 
Study Purpose 
  With the above study being the only retrospective database analysis conducted so far to 
explore the role of statins in the management of asthma, further such studies are warranted.  
Additionally, a definitive conclusion regarding the potential benefits of statins in the treatment of 
asthma has not yet been reached as the various animal model studies and clinical trials described 
above show varying results and have their own limitations.  Thus, another secondary database 
analysis, using a different dataset, will be economically more feasible and will provide us with 
an overview of the situation in the real-world setting.  This study uses a propensity score 
matched cohort study design which in itself should take into account any confounding effects 
due to the variables used to compute the propensity scores.  Prior hospitalizations, ER and office 
visits due to asthma, compliance to ICS medications and average number of short-acting β 
agonists during the study period were used to compute the propensity scores.  These had not 
been taken into account in the study conducted by E. Stanek and colleagues.  Prior 
hospitalizations due to asthma  and average number of short-acting β agonists can be an indicator 
of the severity of the disease, whereas compliance to the medications is a potential confounder as 
it could lead to hospitalization/ER visits.  Thus, conducting a study on a different dataset with a 
different study design will make a significant addition to the research done so far on this topic.  
Moreover, the results of this study will aid in the decision as to whether to design further clinical 
trials on larger scales.    
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Bearing the significance in mind, the purpose of the study is to make explicit the role of 
statins in the management of asthma in the real-world setting.  There seems to be some 
ambiguity concerning the potential anti-inflammatory benefits of the HMG-CoA reductase 
inhibitors for asthmatic patients with the animal model studies and the observational study 
showing positive results and the clinical trials suggesting otherwise.  Thus, this study can provide 
additional evidence to help make the picture clearer, as it will overcome some of the limitations 
of the work done so far. 
To achieve the above purpose, the main objectives of this study are 
1. To describe the baseline characteristics such as age, gender, race of Medicaid 
beneficiaries with asthma who are on statin therapy and those not on statin therapy. 
2. To compare the outcomes, using ER visits and hospitalizations as a measure, amongst 
asthmatic Medicaid beneficiaries on statin therapy to those not on statin therapy. 
3. To compare the costs incurred by asthmatic Medicaid beneficiaries on statin therapy to 
those not on statin therapy including the prescription costs, ER visits and hospitalization 
costs.  
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III. METHODS AND STUDY DESIGN 
A retrospective cohort study of the Mississippi Medicaid claims database was conducted.  
The study involved analysis of the Medicaid beneficiary claims from January 1st 2002 to 
December 31st 2004.  As mentioned earlier, the primary objective of this study was to compare 
the asthma related outcomes- ER visits, hospitalizations- of Medicaid beneficiaries diagnosed 
with asthma and on concurrent statin therapy versus those not on statin therapy.  Apart from this, 
the study also looked into the costs incurred by asthmatic Medicaid beneficiaries on statin 
therapy versus those not on statin therapy in terms of prescription costs, hospitalization and ER 
visits costs.  The study was approved by the Institutional Review Board (IRB) of the University 
of Mississippi.  
 
Data Source  
 Medicaid is a federal health care program that provides health care coverage to many of the 
most vulnerable populations in the United States, including low-income children and their 
parents, low-income elderly, pregnant women with low family income and the disabled poor.  
The program is jointly run by the federal and state governments whereby the former establishes 
general guidelines for the program and the latter decides upon the eligibility criteria.  
The Mississippi Medicaid claims database was used for this study.  It is an administrative 
claims database, comprising of one Person Summary File and four Claims Files - inpatient (IP), 
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institutional long-term care (LT), prescription drug (RX) and other services (OT).  The Person 
Summary File is created to include person level data on eligibility, demographics, managed care 
enrollment, a summary of utilization and Medicaid payment by type of service.  Whereas, each 
observation in the claims files represents a transaction or record of the payment made to the 
health care provider for the services offered by him/her to the Medicaid enrollee, including 
details like the date of service, expenditures for utilized services, associated diagnostic 
information, and provider and procedure type.  The person summary file has a record for every 
individual enrolled in the program at anytime during the year; however, the claims files may 
have more than one or no records for a Medicaid beneficiary depending on his/her utilization of 
the services.  The following variables from each dataset were used in the study: 
1. Medicaid Analytic Extract Personal Summary Record:  It contains a record for each unique 
person, based on his/her MSIS Identification Number, which is a unique number used to 
identify a Medicaid eligible in the Medicaid Statistical Information System (MSIS).  The 
unique encrypted patient identification number was used as the linking variable to club 
records of a particular patient from all the other data files into one file.  The other variables 
that were required from the personal summary record are eligible birth date, eligible sex 
code, eligible race/ethnicity code, eligible residency county and max uniform eligibility code. 
2. Medicaid Analytic Extract Inpatient Record:  The inpatient record provides information on 
inpatient hospital stays for each patient.  The MSIS type of service code, Medicaid payment 
amount, the principal diagnosis code as well as all the other diagnoses codes were the fields 
used from this file. 
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3. Medicaid Analytic Extract Drug Record:  The drug record provides information on drugs and 
other services provided by a pharmacy for each recipient.  The Medicaid payment amount, 
prescription filled date, new or refill indicators, NDC, quantity of service and days’ supply 
were the required fields. 
4. Medicaid Analytic Extract Other Services Record:  The other services record provides 
information on services for each recipient, other than those provided by an inpatient hospital, 
long term care facility or pharmacy.  The diagnoses codes from this record were also used to 
identify asthmatic patients.  Additionally, the procedure codes and place of visit codes were 
used to identify office and lab visits attributed to a primary diagnosis of asthma. 
 
Study Period and Study Population  
The Medicaid records from January 1st 2002 through December 31st 2004 were analyzed.  
It is important to note here that, since the study period under consideration is prior to the 
implementation of Medicare Part D, the database does include elderly patients.  Asthmatic adults 
above 18 years of age were identified using the ICD9 code 493.xx, within the 18 month 
identification period starting July 1st 2002 and concluding December 31st 2003 as graphically 
represented in Figure II.  The index date for a particular subject in the exposed group was any 
date within the identification period, six months prior to which the subject had at least one 
prescription for an inhaled corticosteroid (ICS), at least an 80% adherence rate to statins (i.e. a 
medication possession ratio (MPR) of 0.8), in addition to already having been diagnosed with 
asthma.  The subjects on statin and ICS therapy were identified using the National Drug Codes 
(NDC) for these drugs respectively.  The list of drugs considered has been provided in Appendix 
 16 
 
I. 589 beneficiaries were thus identified to be in the exposed group.  Similarly, Medicaid 
beneficiaries identified as asthmatics and on ICS therapy were selected as the unexposed 
population with the only difference being that these patients were not on concurrent statin 
therapy.  The inclusion criteria for the exposed as well as unexposed groups have been laid out in 
Table I.  
Table I: Inclusion criteria for the ‘exposed’ and ‘unexposed’ groups 
 
 
The study design included a washout period from January 1st 2002 to June 31st 2002 in 
order to track the prescription records of patients identified and included in the study after June 
31st 2002.  The 589 subjects in the exposed group were matched to the 7390 subjects in the 
unexposed group using propensity scores (within a range of ±0.005) computed using certain 
covariates, which shall be explained in detail later.  Each exposed subject was matched to 10 
corresponding subjects from the unexposed group; following which the unexposed subjects were 
assigned the index date of the exposed subjects they were matched to.  This was done in order to 
maximize the number of exposed subjects that had at least 2 corresponding subjects from the 
 ‘EXPOSED’ ‘UNEXPOSED’ 
1. Diagnosed with Asthma   
2. 180 day prescription history of statins prior to the 
index date with a MPR ≥ 0.8 
  
3. At least 1 prescription for an ICS 6 months prior to 
index date 
  
4. Continuous eligibility for a period of 18 months 
beginning 6 months prior to and ending a year 
after the index date 
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unexposed group with an ICS prescription six months prior to the index date and were eligible 
throughout the same period.  479 exposed subjects were thus obtained, along with corresponding 
958 unexposed subjects and a detailed flow diagram representing this has been provided (Figure 
III).  The two cohorts were then followed for a period of one year beginning the index date, and 
their outcomes in terms of hospitalizations and ER visits were compared.   
 
Figure II. Graphical representation of the study design 
 
 
 
Identification of subjects Washout period 
Jan 2002 
 
Jul 2002 
 
Jan 2004 
 
Dec 2004 
 
Oct 2002 
 
Oct 2002 
 
Sep 2003 
 
Sep 2003 
 
Apr 2003 
 
Apr 2003 
Mar 2004 
 
Mar 2004 
 
St
at
in
s 
(‘E
xp
os
ed
’) 
N
o 
st
at
in
s 
(‘U
ne
xp
os
ed
’) 
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III. Algorithm displaying how the final study subjects were identified. 
 
Rationale for including only Asthmatics on Inhaled Corticosteroid Therapy 
Inhaled Corticosteroids (ICSs) are the most consistently effective long-term control 
medication at all steps of care for persistent asthma and they improve asthma control more 
effectively than any other single long-term control medication.2  They are anti-inflammatory 
medications that reduce airway hyper responsiveness, inhibit inflammatory cell migration and 
activation and block late phase reaction to allergens.2  Statins are also hypothesized to be of 
potential benefit in asthma management due to their anti-inflammatory properties and hence only 
83,446 beneficiaries with a diagnosis of asthma 
35,001 beneficiaries with at least 1 ICS prescription 
2,742 beneficiaries with at least 1 statin prescription 
589 ‘exposed’ beneficiaries with ≥80% adherence to 
statin medication and at least 1 ICS prescription over 
a period of 180 days between 1st January 2002 and 
31st December 2003 
479 ‘exposed’ beneficiaries each matched to two 
‘unexposed’ beneficiaries meeting all the inclusion 
criteria enlisted in Table I. 
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those patients on ICS therapy were included in the study design so as to avoid confounding.  If 
being on ICS therapy is not one of the inclusion criteria, the potential beneficial effect of statins 
amongst the exposed population might be mitigated due to patients not on ICS therapy, in case 
there are more subjects in the unexposed group on ICS therapy.  Similarly, the results will be 
affected if a larger number of exposed patients are on ICS therapy as compared to the unexposed.  
ICSs are used for the control of asthma rather than for quick relief of symptoms and thus 
majority of the asthmatic patients are expected to be on ICS therapy.  Thus, it was feasible to 
incorporate it into the study design as an inclusion criterion rather than control for it. 
 
Study Variables 
Covariates:  
The exposed and unexposed groups were matched on the following variables using propensity 
scoring. 
i. Age.  The age of the subjects as of 31st December 2002 was computed using their date of 
birth. 
ii. Gender.  The two categories were:  
Male 
Female 
iii. Race.  The three categories considered were: 
Whites 
Blacks 
Others  
iv. Regions of Mississippi.  The subjects were categorized into Rural and Urban based on the 
county numbers listed in Appendix II.  This variable was used to serve as an indication of the 
access to care and control for differences in provider type.  
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v. Comorbidities.  The Charlson Comorbidity Index (CCI) was computed and used in the 
calculation of the propensity scores.  
The following variables were additionally controlled for in the analysis performed on the 
matched cohorts. 
i. Adherence to ICS.  The MPR was used as an indication of adherence to ICS therapy and was 
computed for the six months prior to the index date for each subject53. 
ii. Average number of short-acting β agonists per subject.  Short-acting β agonists are the most 
effective therapy for rapid reversal of airflow obstruction and prompt relief of asthmatic 
symptoms.  The average number of short-acting β agonists per subject was computed for the 
six months prior to the index date and was used as an indicator of the severity of the disease.  
The list of drugs considered has been provided in Appendix I. 
iii. Prior hospitalizations due to asthma.  The number of hospitalizations attributed to a primary 
diagnosis of asthma in the six month washout period prior to the index date was used as an 
indicator of the severity of the disease. 
iv. Prior ER visits due to asthma.  In addition to the inpatient visits, the number of ER visits 
attributed to a primary diagnosis of asthma in the six month washout period prior to the index 
date was also used as an indicator of the severity of the disease. 
v. Prior office and lab visits due to asthma.  The number of office and lab visits attributed to a 
primary diagnosis of asthma six months prior to the index date was accounted for as an 
additional measure of severity of the disease. 
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Outcome variables 
i. Hospitalization due to asthma.  Hospitalization due to asthma was one of the outcome 
variables based on which the exposed subjects were compared against the unexposed group.  
The variable was coded dichotomously (as occurrence and non-occurrence of event), using 
the principal diagnosis code for hospitalization, through one year post the index date for both 
the exposed and unexposed groups. 
ii. ER visits due to asthma.  ER visit was used as a measure of the outcomes similar to the 
hospitalization visits.  Again the occurrence or non-occurrence of an ER visit one year post 
the index date for each subject was computed. 
iii. Costs due to asthma.  The prescription, inpatient visit, ER visit, office and lab visit costs due 
to asthma, from Medicaid’s perspective, was used to calculate the costs incurred.  The 
prescription costs due to statins will be taken into account for the exposed group.  
 
Analysis Plan 
The following two hypotheses were tested using the described analyses. 
Hypothesis 1: Asthmatic patients on concurrent statin therapy are less likely to have asthma-
related hospitalizations and ER visits. 
Hypothesis 2: Asthmatic patients on concurrent statin therapy bear lesser costs due to the 
management of asthma.  
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Descriptive statistics were reported for the exposed and unexposed subjects pre- and post-
matching.  PROC MEANS with the t-test option specified was used to compute mean and 
standard deviations along with differences in the average age and CCI of the two cohorts pre- 
and post-matching.  Similarly, PROC FREQ was used to compute frequencies and percentages 
for categorical variables such as gender, race and region and to determine differences in 
percentages across these variables between the two cohorts pre- and post matching. 
 After the identification of the exposed and unexposed based on the inclusion criteria 
described previously, propensity scores (PS) were calculated for the subjects in both groups.  The 
propensity score for an individual is defined as the conditional probability of being treated given 
the individual’s covariates and thus reduces bias by balancing the covariates in the two groups.  
PROC LOGISTIC was used to compute and save the probability of being in the exposed group 
for all subjects based on their age, gender, race, region and CCI as discussed previously. 
After the matched exposed and unexposed cohorts were obtained, the two groups were 
analyzed using conditional logistic regression, via PROC LOGISTIC with the STRATA option 
specified, to compare the hospitalization and ER visits and test hypothesis 1.  The difference in 
the costs accrued by the two groups was analyzed using a general linear model accounting for the 
dependencies in the data.  
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IV. RESULTS 
As discussed previously, 589 subjects met the inclusion criteria for the exposed cohort 
and the pool of unexposed subjects comprised of 7,390 individuals prior to matching on the 
propensity scores.  The average age of asthma patients on concurrent statin therapy was 
significantly higher than that of patients not on statin therapy (48.87 [±0.22] vs. 63.28 [±0.5]; p < 
0.0001).  A significantly higher proportion of asthma patients who were not on concurrent statin 
therapy were black as compared to those on statin therapy (54.44% vs. 42.95%; p < 0.0001) 
before matching (Table II).  Additionally, those on concurrent statin therapy had a significantly 
higher average CCI than those not on concurrent statin therapy (4.01[±0.10] vs. 2.65 [± 0.03]; p 
< 0.0001).  
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Table II. Sample descriptives before matching 
 
 
 
 
 
 
 
 
 
* p < 0.05 
 
The spread of the computed propensity of being in the exposed cohort for each subject in 
the study before matching is displayed in Figure IV. 
Characteristic Exposed (589) 
Unexposed  
(7390) P 
Age, mean (SD) 63.28 (± 0.50) 48.87 (± 0.22) <.0001* 
    
Gender, n (%)   0.5750 
Male 125 (21.22%) 1642 (22.22%)  
Female 464 (78.78%) 5748 (77.78%)  
    
Race, n (%)   <.0001* 
White 334 (56.71%) 3321 (44.94%)  
Black  253 (42.95%) 4023 (54.44%)  
Other 2 (0.34%) 46 (0.62%)  
    
Region, n (%)   0.0544 
Urban 167 (28.35%) 2379 (32.19%)  
Rural 422 (71.65%) 5011 (67.81%)  
    
Charleson Comorbidity Index, 
mean (SD) 4.01 (± 0.10) 2.65 (± 0.03) <.0001* 
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Figure IV. Distribution of propensity scores before matching 
 
After matching, the exposed cohort comprised of 479 individuals with 958 individuals in 
the unexposed cohort.  Post-matching on propensity scores, a significantly higher proportion of 
asthma patients on concurrent statin therapy were from the rural areas of Mississippi (71.19% vs. 
65.45%; p = 0.0287) as compared to those not on statin therapy (Table III).  Additionally, the 
average CCI of patients on concurrent statin therapy was higher than that of patients not on statin 
therapy (3.75 [±0.10] vs. 3.48 [±0.07]; p = 0.03).  
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Table II. Sample descriptives after matching 
 
 
 
 
 
 
 
 
* p < 0.05 
 
 
The range of the propensity scores of each individual in the study post-matching has been 
shown in Figure V. 
 
 
Characteristic Exposed (479) 
Unexposed 
(958) P 
    
Age, mean (SD) 62.59 (0.55) 63.48 (0.42) 0.2124 
    
Gender, n (%)   0.1994 
Male 101 (21.09%) 231 (24.11%)  
Female 378 (78.91%) 727 (75.89%)  
    
Race, n (%)   0.4716 
White 269 (56.16%) 540 (56.37%)  
Black 208 (43.42%) 417 (43.53%)  
Other 2 (0.42%) 1 (0.1%)  
    
Region, n (%)   0.0287* 
Urban 138 (28.81%) 331 (34.55%)  
Rural 341 (71.19%) 627 (65.45%)  
    
Charleson Comorbidity 
Index, mean (SD) 3.75 (±0.10) 3.48 (±0.07) 0.0300* 
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Figure V. Distribution of propensity scores after matching 
 
The proportion of exposed and unexposed subjects using additional medications, besides 
ICS, for asthma management has been reported in Table IV. 
Table IV. Additional medications used for asthma management  
Medication Exposed (479) n (%) 
Unexposed 
(958) 
n (%) 
Mast cell stabilizers 2 (<1) 5 (<1) 
Leukotriene modifiers 134 (28) 318 (33) 
Long- acting β agonists 48 (10) 126 (13) 
Theophylline 42 (9) 142 (15) 
Ipratropium 31 (6) 100 (10) 
Short-acting  β agonists (SABA) 180 (38) 462 (48) 
Oral corticosteroids 81 (17) 294 (31) 
* The list of drugs considered for each of the above classes has been provided in Appendix I 
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Descriptive information on the various covariates adjusted for in the final conditional 
logistic regression model has been provided in Table V. 
Table V. Descriptives of covariates adjusted for 
Characteristic 
Exposed  
(479) 
mean, (SD) 
Unexposed 
(958) 
mean, (SD) 
P value 
Adherence to ICS therapy (Proportion of days covered) 0.47 (0.2684) 
0.51 
(0.2811) 
0.0146* 
Average no. of SABA prescriptions per subject 2.74 (2.10) 3.49 (2.85) <.0001* 
No. of asthma office & lab visits 6 months prior the 
index date 
0.21 
(0.6375) 
0.24 
(0.6535) 0.5031 
No. of asthma hospitalization events 6 months prior the 
index date 
0.03 
(0.1860) 
0.05 
(0.2406) 
0.1002 
No. of asthma ER events 6 months prior the index date 0.02 (0.1359) 
0.06 
(0.2908) 
0.0063* 
* p < 0.05 
The proportion of the exposed and unexposed subjects where the occurrence of the 
outcome events were observed, have been reported in Table VI.   
Table VI. Occurrence of the outcomes studied 
Outcome 
Exposed  
(479) 
n (%) 
Unexposed 
(958) 
n (%) 
≥1 asthma hospitalization events 12 months post index date 19 (3.79) 62 (6.47) 
≥1 asthma ER events 12 months post index date 20 (4.18) 87 (9.08) 
 
Table VII represents the results of the conditional logistic regression conducted on the 
matched data to obtain the odds of hospitalization/ER admission due to asthma amongst patients 
on concurrent statin therapy as opposed to those not on statin therapy.  Asthma patients not on 
concurrent statin therapy were almost two times as likely to have hospital visits and/or ER visits 
or both due to asthma (unadjusted OR = 0.51; 95% CI [0.34, 0.76]), in comparison to patients on 
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statin therapy.  Similarly, they were also more likely to be hospitalized (unadjusted OR = 0.56; 
95% CI [0.32, 0.98]) and visit the ER (unadjusted OR = 0.44; 95% CI [0.27, 0.73]) due to 
asthma exacerbations as opposed to those on statin therapy.  The above odds ratios have not been 
adjusted for additional variables such as prior asthma-related hospitalizations, ER visits, office 
and lab visits and adherence to ICS therapy.  The adjusted conditional odds ratios after 
accounting for all the above mentioned factors have also been reported in Table VII.  Asthma 
patients not on concurrent statin therapy were almost two times as likely to have hospitalization 
and/or ER visits or both due to asthma (adjusted OR = 0.55; 95% CI [0.36, 0.84]; p = 0.0059), in 
comparison to patients on statin therapy. Similarly, they were also significantly more likely to 
visit the ER due to asthma exacerbations when compared to patients on statins (adjusted OR = 
0.47; 95% CI [0.28, 0.82]; p = 0.0069). 
Table VII. Conditional odds ratios of hospitalizations due to asthma associated with statin use. 
* p < 0.05 
 
 When the costs incurred per subject due to asthma were compared across the two groups, 
the average prescription costs due to asthma ($1,166 [± $1,005] vs. $1,536 [± $1,303]; p = 
<.0001), hospitalization ($125 [±$710] vs. $252[±1,264]; p = 0.0376) and ER visit ($3 [± $19] 
vs. $10 [± $47]; p <.0013) costs incurred by patients not on concurrent statin therapy over the 
study period (18 months) are significantly higher (Table VIII).  Similarly, the average total costs 
Outcome Unadjusted OR (95% CI) P value 
Adjusted OR 
(95% CI) P value 
Asthma hospitalization 
and/or ER visit 
0.511 
(0.342 – 0.762) 0.0010* 
0.547 
(0.356 – 0.840)   0.0059* 
Asthma hospitalization 0.562 (0.321 – 0.983) 0.0436* 
0.629 
(0.352 – 1.125) 0.1183 
Asthma ER visit 0.442 (0.269 – 0.726) 0.0013* 
0.474 
(0.275 – 0.815)   0.0069* 
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inclusive of prescription, hospitalization, ER, office and lab visit costs due to asthma were 
significantly higher for patients not on concurrent statin therapy when compared to those on 
statin therapy ($1,852 [± $1,944] vs. $1,337[$1,264]; p <.0001).  However, when the 
prescription costs due to statins are included for the exposed patients, the average total costs 
were significantly higher for patients on concurrent statin therapy when compared to those not on 
statin therapy ($2,578 [$1,373] vs. $1,852 [$1,944]; p < .0001). 
Table VIII. Average costs incurred per patient over the study period (18 months) 
Costs  Exposed (479), mean (SE) 
Unexposed (958), 
mean (SE) P 
Due to asthma    
Prescription $1,166 ($1,005) $1,536 ($1,303)            <.0001* 
Hospitalization  $125 ($710) $252 ($1,264) 0.0376* 
ER  $3 ($19) $10 ($47) 0.0013* 
Office & lab  $42 ($116) $53 ($128)             0.0961 
Total  $1,337 ($1,264) $1,852 ($1,944) <.0001* 
    
Statin therapy costs $1,241 ($501) NA NA 
Total  $2,578 ($1,373) $1,852 ($1,944) <.0001* 
* p < 0.05 
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V. DISCUSSION 
This study aims at exploring the benefits of statins on asthma outcomes such as ER visits 
and hospitalizations, using the Mississippi Medicaid claims data (2002-2004).  Using a 
retrospective cohort study design we compared the outcomes of asthma patients on concurrent 
statin therapy versus those not on statin therapy.  Further the costs incurred by Medicaid due to 
asthma were also compared across the two groups. 
Over the three years of data analyzed, 589 subjects met the inclusion criteria for the 
exposed cohort, prior to matching and were classified as subjects on statin therapy, with 7,390 
subjects in the unexposed cohort.  When comparing the demographic characteristics of patients 
on concurrent statin therapy to those not on statins, significant differences were observed.  The 
average age of the asthmatic patients on statin therapy was significantly higher than those not on 
statin therapy.  This is not surprising as patients with statin therapy would likely have a co-
diagnosis of hyperlipidemia, a condition more prevalent in older adults.  Additionally, a 
significantly higher proportion of patients on statin therapy were white when compared to the 
unexposed population and also had a higher average CCI score.  In order to control for the above 
differences, propensity scores were computed and the study groups were matched on their 
propensity to be in the exposed cohort.  The two groups could have been directly matched on 
each of the covariates listed in Table II; however, this would lead to a considerable decrease in 
the sample size and hence was not preferred.  Additionally, the outcome events, i.e. 
hospitalizations and ER visits due to asthma 12 months post the index date, were observed in 
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5.67% and 7.4% of the study subjects, respectively.  This can be considered a rare outcome and 
therefore, using propensity scores was considered suitable.   After matching, there were 479 
subjects in the exposed group and 958 corresponding controls.   
The final sample comprised of considerably older subjects with the average age of the 
exposed and unexposed being 62.59 (±0.55) years and 63.48 (±0.42) years, respectively.  A 
majority of them were females, which is consistent with previous prevalence reports which 
indicate that asthma is more prevalent in females21 in general.  Additionally, a higher proportion 
of the sample was white, belonged to rural regions and had a considerable number of comorbid 
conditions as is evident from the higher average CCI score.   
A higher proportion of the unexposed subjects were on additional asthma controller 
therapy, besides ICS, such as mast cell stabilizers, leukotriene modifiers, long-acting β agonists, 
theophylline, ipratropium, short-acting β agonists and oral corticosteroids.  Short-acting β 
agonists are the most effective therapy for rapid reversal of airflow obstruction and prompt relief 
of asthmatic symptoms.25  Thus, the average number of short-acting β agonist prescriptions per 
patient was controlled for in the final analysis as an indicator of the severity of the condition.  It 
is interesting to note however, that the average number of short-acting β agonist prescriptions 
were significantly higher for patients not on statin therapy and thus one might expect their 
condition to be better managed, which does not seem to be the case.  Thus, the other way to look 
at it is that their condition is more severe or is not being managed well and hence the higher 
average number of quick relief prescriptions. 
The additional factors controlled for included adherence to ICS therapy, average number 
of short-acting β agonist prescriptions per subject, prior hospitalizations, ER, lab and office visits 
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due to asthma.  The adherence to ICS therapy among the study subjects was considerably low, 
with the exposed and unexposed subjects being 47% and 51% adherent, respectively.  It is 
important to note here that the unexposed cohort in this study did have higher adherence rates to 
ICS therapy.  Systematic reviews conducted by the Cochrane collaboration of the adherence to 
ICS therapy literature, also suggest underuse of prescribed ICSs on 24% to 69% of days.54  
Additional studies assessing prescription refills of ICSs report MPRs within a range of 8% to 
50%.53,55-58  Thus the low adherence among our study subjects is not surprising, and was 
controlled for as it is associated with adverse asthma outcomes.  However, this also brings to 
light that adherence to ICS therapy is a problem and more effort is required to help patients 
better manage their asthma.  
The average number of asthma hospitalizations, ER, office and lab visits per subject over 
a period of 6 months is consistent with the rates reported by the National Surveillance for 
Asthma 2001-2003.21  The report mentions an average annual 61.2 office visits, 8.8 ER visits and 
2.5 hospitalizations for asthma per 100 persons with current asthma.   
A significant reduction in the odds of hospitalization and ER visits due to asthma was 
found to be associated with statin use.  Even after controlling for the cofounders mentioned 
above, patients not on concurrent statin therapy were almost twice as likely to have 
hospitalization and/or ER visits attributable to asthma when compared to patients on statin 
therapy.  These findings are in accordance with the only other observational study13 conducted to 
investigate the beneficial effects of statins in asthma therapy.  The authors reported that statin 
therapy was associated with a 33% lower risk of hospitalization or ER visit for asthma in adult 
asthmatic patients on inhaled corticosteroid therapy.  The difference in the results reported in our 
study could be attributable to the differences in the dataset as well as methodology used.  We 
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conducted our analyses on matched cohorts and additional factors such as adherence to ICS 
medication, prior hospitalizations, ER, lab and office visits due to asthma were accounted for, in 
order to control for the severity of the condition.  Additionally, the proportions of subjects in 
both groups on additional controller medications for asthma have also been reported.  Although, 
the study conducted by Stanek and colleagues is the only other that analyzes claims data, further 
support for the beneficial role of statins in asthma is found in numerous animal model studies.4-10 
There are several limitations of this study.  The study was conducted using Medicaid 
claims data and therefore there is a possibility of misclassification due to coding errors during 
claims processing.  Further, even though the subjects in the unexposed group were matched to 
the exposed population based on their propensity scores, significant differences between the two 
groups were still observed when compared across their CCI scores and the region (urban versus 
rural) to which they belonged.  This could be attributed to two plausible explanations. Firstly, the 
cohorts were matched on propensity scores allowing a range of ±0.005.  Secondly, each subject 
was initially matched to 10 corresponding subjects from the unexposed pool, following which 
two controls were selected based on their continuous eligibility throughout the study period and 
ICS prescription records within 180 days prior to the index date.  However, both of the above 
measures were incorporated into the study design to maximize the sample size.  The subjects on 
statin therapy had a significantly higher average CCI score compared to those not on statin 
therapy.  It is unlikely that this difference could have biased the findings towards a lower risk of 
hospitalization due to asthma in these subjects.  Further, the average age of the population 
studied was around 63 years, which suggests that a considerable number of subjects were dual-
eligibles.  Thus some might suggest that all the claims for this population might not be present in 
the dataset as Medicare is their primary payer.  However, since Medicaid contributes towards the 
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copayment one can argue that the claim would still be present in the dataset; however, the total 
costs associated with that claim will not be available.  Thus, although this should not bias the 
results of the conditional logistic regression, a potential limitation would be that the costs 
associated with asthma hospitalization are likely to be underestimated.  Additionally, the 
population studied had an average age of approximately 63 years and were sicker patients in 
general due to the higher CCI scores, which limits the generalizability of the study to some 
extent. 
The total average per person cost of asthma over the study period (18 months) is $1,337 
(±$1,264) for those on concurrent statin therapy and $1,852 (±$1,944) for those not on statins.  
However, when statin prescription costs are included, the average total costs for the exposed 
group amounts to $2,578 (±1,373).  Thus, the results are not in favor of our proposed hypotheses.  
However, these need to be interpreted with caution as they may be underestimated, as mentioned 
above, due to dual-eligibility.  The average direct annual cost of asthma per-person reported 
using cross-sectional survey data of 401 adults with asthma is $3,180,59 which is higher than the 
costs reported in our study.  Further the average ER and hospitalization costs reported in our 
study are very low.  An explanation for this observation may be the fact that these events were 
observed in few patients thus decreasing the average considerably. 
The findings of this study contribute significantly to the growing body of literature that 
suggests statins have beneficial effects in preventing asthma exacerbations.  However, further 
investigation employing different datasets, different methodologies and accounting for other 
confounding variables which may have been overlooked, is required to provide conclusive 
evidence.  Although, two clinical trials11,12 conducted earlier have failed to show clinically 
important improvements in asthma symptoms and a range of other clinical indices in asthma 
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control, these suffer from sample size limitations and hence their results should be interpreted 
with caution.  Further, the results of a recent animal model study 10, although supporting the anti-
inflammatory effects of simvastatin suggest that the effect of simvastatin on lung inflammation 
in asthma are controversial and differ between species.  Thus, in the light of the evidence so far, 
and considering the results of this study, the role of statins in the treatment of asthma definitely 
warrants further investigation. 
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APPENDIX I 
List of statins and statin combinations considered 
• Amlodipine-atorvastatin 
• Aspirin-pravastatin 
• Atorvastatin 
• Cerivastatin 
• Ezetimibe-simvastatin 
• Fluvastatin 
• Lovastatin 
• Lovastatin-niacin 
• Niacin-simvastatin 
• Pravastatin 
• Rosuvastatin 
• Simvastatin 
 
List of inhaled corticosteroids and combination drugs with inhaled corticosteroids considered 
• Beclomethasone 
• Budenoside 
• Budesonide-formoterol 
• Ciclesonide 
• Flunisolide 
• Fluticasone 
• Fluticasone-salmeterol 
• Mometasone 
• Triamcinolone 
 
List of drugs considered as additional controller therapy for asthma management 
 Mast cell stabilizers 
• Cromolyn 
• Nedocromil 
 
 Leukotriene modifiers 
• Montelukast 
• Zafirlukast 
• Zileuton 
 
 Long-acting β agonists 
• Formoterol 
• Salmeterol 
 
 Methylxanthines 
• Theophylline 
 
 Short-acting β agonists 
• Albuterol 
• Levalbuterol 
• Pirbuterol 
 
 Systemic corticosteroids 
• Methylprednisolone 
• Prednisolone 
• Prednisone 
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APPENDIX II 
 
Rural/Urban county codes for counties in Mississippi 
FIPS 
Code State County Name 
2003 Rural-
urban 
Continuum 
Code 
2000 
Population Description for 2003 codes 
Rural/Urban code 
used in study 
28003 MS Alcorn County 7 34,558 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28005 MS Amite County 8 13,599 Nonmetro county completely rural or less than 2,500 urban population, adj. to metro area 0 
28007 MS Attala County 6 19,661 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28009 MS Benton County 8 8,026 Nonmetro county completely rural or less than 2,500 urban population, adj. to metro area 0 
28011 MS Bolivar County 5 40,633 Nonmetro county with urban population of 20,000 or more, not adjacent to a metro area 0 
28013 MS Calhoun County 7 15,069 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28015 MS Carroll County 9 10,769 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28017 MS Chickasaw County 7 19,440 
Nonmetro county with urban population of 2,500-19,999, not adjacent to a 
metro area 0 
28019 MS Choctaw County 9 9,758 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28021 MS Claiborne County 6 11,831 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28023 MS Clarke County 9 17,955 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28025 MS Clay County 7 21,979 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28027 MS Coahoma County 5 30,622 Nonmetro county with urban population of 20,000 or more, not adjacent to a metro area 0 
28029 MS Copiah County 2 28,757 County in metro area of 250,000 to 1 million population 1 
28031 MS Covington County 8 19,407 
Nonmetro county completely rural or less than 2,500 urban population, adj. to 
metro area 0 
28033 MS DeSoto County 1 107,199 County in metro area with 1 million population or more 1 
28035 MS Forrest County 3 72,604 County in metro area of fewer than 250,000 population 1 
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28037 MS Franklin County 9 8,448 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28039 MS George County 3 19,144 County in metro area of fewer than 250,000 population 1 
28041 MS Greene County 8 13,299 Nonmetro county completely rural or less than 2,500 urban population, adj. to metro area 0 
28043 MS Grenada County 7 23,263 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28045 MS Hancock County 3 42,967 County in metro area of fewer than 250,000 population 1 
28047 MS Harrison County 3 189,601 County in metro area of fewer than 250,000 population 1 
28049 MS Hinds County 2 250,800 County in metro area of 250,000 to 1 million population 1 
28051 MS Holmes County 6 21,609 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28053 MS Humphreys County 7 11,206 
Nonmetro county with urban population of 2,500-19,999, not adjacent to a 
metro area 0 
28055 MS Issaquena County 9 2,274 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28057 MS Itawamba County 7 22,770 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28059 MS Jackson County 3 131,420 County in metro area of fewer than 250,000 population 1 
28061 MS Jasper County 9 18,149 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28063 MS Jefferson County 7 9,740 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28065 MS Jefferson Davis County 8 13,962 
Nonmetro county completely rural or less than 2,500 urban population, adj. to 
metro area 0 
28067 MS Jones County 4 64,958 Nonmetro county with urban population of 20,000 or more, adjacent to a metro area 0 
28069 MS Kemper County 9 10,453 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28071 MS Lafayette County 6 38,744 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28073 MS Lamar County 3 39,070 County in metro area of fewer than 250,000 population 1 
28075 MS Lauderdale County 5 78,161 
Nonmetro county with urban population of 20,000 or more, not adjacent to a 
metro area 0 
28077 MS Lawrence County 8 13,258 Nonmetro county completely rural or less than 2,500 urban population, adj. to metro area 0 
28079 MS Leake County 6 20,940 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28081 MS Lee County 5 75,755 Nonmetro county with urban population of 20,000 or more, not adjacent to a metro area 0 
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28083 MS Leflore County 5 37,947 Nonmetro county with urban population of 20,000 or more, not adjacent to a metro area 0 
28085 MS Lincoln County 6 33,166 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28087 MS Lowndes County 5 61,586 Nonmetro county with urban population of 20,000 or more, not adjacent to a metro area 0 
28089 MS Madison County 2 74,674 County in metro area of 250,000 to 1 million population 1 
28091 MS Marion County 6 25,595 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28093 MS Marshall County 1 34,993 County in metro area with 1 million population or more 1 
28095 MS Monroe County 7 38,014 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28097 MS Montgomery County 7 12,189 
Nonmetro county with urban population of 2,500-19,999, not adjacent to a 
metro area 0 
28099 MS Neshoba County 7 28,684 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28101 MS Newton County 7 21,838 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28103 MS Noxubee County 7 12,548 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28105 MS Oktibbeha County 5 42,902 
Nonmetro county with urban population of 20,000 or more, not adjacent to a 
metro area 0 
28107 MS Panola County 6 34,274 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28109 MS Pearl River County 6 48,621 
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro 
area 0 
28111 MS Perry County 3 12,138 County in metro area of fewer than 250,000 population 1 
28113 MS Pike County 7 38,940 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28115 MS Pontotoc County 7 26,726 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28117 MS Prentiss County 7 25,556 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28119 MS Quitman County 6 10,117 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28121 MS Rankin County 2 115,327 County in metro area of 250,000 to 1 million population 1 
28123 MS Scott County 6 28,423 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
28125 MS Sharkey County 9 6,580 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28127 MS Simpson County 2 27,639 County in metro area of 250,000 to 1 million population 1 
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*Information available at http://www.ers.usda.gov/Data/RuralUrbanContinuumCodes/ 
28129 MS Smith County 8 16,182 Nonmetro county completely rural or less than 2,500 urban population, adj. to metro area 0 
28131 MS Stone County 3 13,622 County in metro area of fewer than 250,000 population 1 
28133 MS Sunflower County 5 34,369 
Nonmetro county with urban population of 20,000 or more, not adjacent to a 
metro area 0 
28135 MS Tallahatchie County 7 14,903 
Nonmetro county with urban population of 2,500-19,999, not adjacent to a 
metro area 0 
28137 MS Tate County 1 25,370 County in metro area with 1 million population or more 1 
28139 MS Tippah County 7 20,826 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28141 MS Tishomingo County 8 19,163 
Nonmetro county completely rural or less than 2,500 urban population, adj. to 
metro area 0 
28143 MS Tunica County 1 9,227 County in metro area with 1 million population or more 1 
28145 MS Union County 7 25,362 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28147 MS Walthall County 9 15,156 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28149 MS Warren County 4 49,644 Nonmetro county with urban population of 20,000 or more, adjacent to a metro area 0 
28151 MS Washington County 5 62,977 
Nonmetro county with urban population of 20,000 or more, not adjacent to a 
metro area 0 
28153 MS Wayne County 7 21,216 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28155 MS Webster County 9 10,294 Nonmetro county completely rural or less than 2,500 urban population, not adj. to metro area 0 
28157 MS Wilkinson County 8 10,312 
Nonmetro county completely rural or less than 2,500 urban population, adj. to 
metro area 0 
28159 MS Winston County 7 20,160 Nonmetro county with urban population of 2,500-19,999, not adjacent to a metro area 0 
28161 MS Yalobusha County 7 13,051 
Nonmetro county with urban population of 2,500-19,999, not adjacent to a 
metro area 0 
28163 MS Yazoo County 6 28,149 Nonmetro county with urban population of 2,500-19,999, adjacent to a metro area 0 
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